We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.

Research and Development

Our Research and Development team

We're working alongside you to develop novel products that remove obstacles in your gene therapy bioproduction workflow.



Innovating for the future of health


We're investing in the discovery of novel products designed to give you a competitive advantage in your work. With custom manufacturing capabilities that fit seamlessly into your cell and gene therapy workflow and our in-house scientific expertise, we can be a true partner to you, helping you overcome bioprocessing challenges and accelerate your breakthroughs.

By scientists, 
for scientists

We launched our Research and Development initiative in 2021, bringing together a talented team of scientists with diverse specialties including synthetic biology, cell line engineering and development, cloning, downstream processing, advanced analytics, and viral production. Our intimate understanding of your workflow helps us make solutions possible. 


Advancing AAV bioprocessing solutions

Our current focus is on supporting customers working in cell and gene therapy with our custom capabilities and products. To truly understand your specific challenges, we have outfitted our laboratory with a complete end-to-end solution for AAV production, purification, and analyses. This includes plasmid construction and scaleup, suspension-based viral production, a downstream processing suite with multiple AKTAs, and state of the art analytical instrumentation for total characterization.

Our novel products

Our proprietary products include our AAV•Tek™ AEX Buffer Screening Kits that enable you to quickly find your optimal buffer formulation for full capsid enrichment, as well as an AAV sample prep kit for PCR analysis that can improve the accuracy of your analytics.

Our research


Together, we conducted a robust design of experiments (DOE) and successfully created highly-customized buffer formulations that drive consistency and increased AAV purity when paired with the BIA CIMmultus® QA monolith.


The buffers and parameters discovered in this study were then further optimized to create our first-of-its-kind AAV•Tek AEX Buffer Screening Kit, which is now available for AAV2 and AAV8.



Teknova x Sartorius

See the data

Our collaborative research shows the successful achievement of over 85% full AAV capsid enrichment with 80-90% recoveries when pairing optimized equilibration and elution buffers from our AAV•Tek AEX Buffer Screening Kit with Sartorius BIA Separations' BIA CIMmultus® QA monolith at the polishing step, given a specific starting material of AAV8 that contained 46% full capsids.


Watch our webinar to see the detailed results of the study.



Working together to
make solutions possible

“Our collaboration with Teknova has demonstrated two essential components for the successful separation of AAV empty and full capsids during the downstream polishing step: the purification platform and the buffer composition. By combining our strengths, we’ve been able to consistently reproduce results that indicate the use of Teknova’s high-quality, custom buffer formulations with our CIMmultus QA monolith increases the yield and purity of full AAV particles.”


- Aleš Štrancar, Managing Director at Sartorius BIA Separations



Be first to try our novel products

Join our Early Access Program to get advance access to our latest products, including our AAV•Tek™ AEX Buffer Screening Kits for additional serotypes. Email us at to learn more.

Join our Early Access Program


We are actively looking for partners to participate in our Early Access Program. You'll gain exclusive access to products we have in development and get the opportunity to provide feedback that can shape their design.

Get in touch to learn more


Monday to Friday

8:00AM–5:00PM PT

Discover more about us


Our history
Join our team
How we give back